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Developmental Biology, University of Massachusetts Medical School, Worcester, MA 01655; kDepartment of Biochemistry, Faculty of Science,
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ABSTRACT
Pseudomonas aeruginosa, a Gram-negative bacterium, is one of the most common pathogens colonizing the lungs of cystic fibrosis
patients. P. aeruginosa secrete extracellular vesicles (EVs) that contain LPS and other virulence factors that modulate the host’s innate
immune response, leading to an increased local proinflammatory response and reduced pathogen clearance, resulting in chronic
infection and ultimately poor patient outcomes. Lung macrophages are the first line of defense in the airway innate immune response
to pathogens. Proper host response to bacterial infection requires communication between APC and T cells, ultimately leading to
pathogen clearance. In this study, we investigate whether EVs secreted from P. aeruginosa alter MHC Ag expression in lung
macrophages, thereby potentially contributing to decreased pathogen clearance. Primary lung macrophages from human subjects
were collected via bronchoalveolar lavage and exposed to EVs isolated from P. aeruginosa in vitro. Gene expression was measured
with the NanoString nCounter gene expression assay. DNA methylation was measured with the EPIC array platform to assess changes
in methylation. P. aeruginosa EVs suppress the expression of 11 different MHC-associated molecules in lung macrophages.
Additionally, we show reduced DNA methylation in a regulatory region of gene complement factor B (CFB) as the possible
driving mechanism of widespread MHC gene suppression. Our results demonstrate MHC molecule downregulation by
P. aeruginosa–derived EVs in lung macrophages, which is consistent with an immune evasion strategy employed by a prokaryote
in a host–pathogen interaction, potentially leading to decreased pulmonary bacterial clearance. ImmunoHorizons, 2020, 4: 508–519.
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INTRODUCTION
Cystic fibrosis (CF) is the most common fatal genetic disease that
occurs in whites (1), with nearly 30,000 individuals diagnosed in
the United States and an estimated 70,000 individuals afflicted
worldwide (2). CF manifests predominantly as a pulmonary
disease but also affects gastrointestinal, endocrine/exocrine, and
reproductive function. CF is caused by a mutation in a gene that
encodes the CF transmembrane conductance regulator (CFTR), a
chloride and bicarbonate ion transport channel that maintains
osmotic balance across multiple epithelial surfaces in the body
(3, 4). Ultimately, 90% of deaths in CF patients are attributed to
pulmonary dysfunction directly associated with chronic infection,
underscoring the absolute importance of studying the pathogen-
esis of CF-relevant microbes (5).
P. aeruginosa is an opportunistic pathogen that commonly
colonizes the lung in CF patients, resulting in an accelerated
decline of pulmonary function (6).
P. aeruginosa is the most dominant pathogen of the lung
microbiota of adultCFpatients andcommonly infects pediatricCF
patients (7). Chronic infection with Gram-negative pathogens of
CF, including P. aeruginosa and Burkholderia cepacia, is associ-
ated with a rapid decline in pulmonary function, more frequent
exacerbations, and higher rates of mortality (8). P. aeruginosa
resides primarily in the mucus overlying lung epithelial cells and
secretes extracellular vesicles (EVs) that diffuse through the
mucus and fusewith airway cells, thus delivering virulence factors
andother toxins into thehost cell cytoplasm thatmodify the innate
immune response (9–14).
EVs are lipid bilayer vesicles secreted by most eukaryotic and
many prokaryotic cells and thought to be intimately involved in
trans-kingdomcross-talk (13, 15–17). EVs can range in size from20
to 1000 nM, depending on the producing cell and its environment
(18). Gram-negative bacterial EVs contain LPS, a known virulence
factor, on their surface (19). Moreover, it has been suggested that
microbial EVs have important and underappreciated roles in
intrakingdom and interkingdom communication by regulating
gene expression in target cells directly and indirectly via host
immune receptor signaling (18).
Ag presentation is crucial for immune responses. MHC
molecules present peptides to other immune cells to mount an
adaptive immune response (20). The host response to bacterial
infection requires communication between APC and T cells. This
communication is relayed through MHC class II Ag presentation
toTh cells, followedby adaptiveT cell orB cell responses (21). The
interaction between T cells and MHC class II, along with the
surrounding milieu, is essential for defining the phenotype and
success of the inflammatory response to infection.
MacrophagesareakeyAPCof the lungandpossess remarkable
immune plasticity, with the ability to sense and adapt to the local
microenvironment (22, 23). Lung macrophages play pivotal roles
in bacterial recognition and elimination as well as in polarization
of innate and adaptive immunity. Depending on the local
setting, macrophages sometimes play a role in anti-inflammatory
responses, tissue repair, and homeostasis, whereas at other times,
they promote inflammatory and phagocytic processes through
the complex production of cytokines and cellular interaction
(24, 25).
Numerouspathogens employa strategy of host immuneescape
during infection, including MHC molecule modulation (26–29).
EVs from the periodontal Gram-negative pathogen, Porphyromo-
nas gingivalis have been shown to inhibit surface expression of
HLA-DRmolecules in human umbilical cord vascular endothelial
cells (30). Additionally, CFTR inhibitory factor (Cif ) protein, a
bacterial virulence factor secreted in EVs by P. aeruginosa, has
been shown to inhibit MHC class I Ag presentation in airway
epithelial cells (10).
The goal of this study is to assess whether EVs isolated from
one of the most prevalent CF pathogens, P. aeruginosa, can alter
expression of MHC-related molecules in lung macrophages,
thereby potentially modulating the macrophages’ ability to mount
a proper immune response to the infection.
MATERIALS AND METHODS
This study was approved by the Dartmouth-Hitchcock Institu-
tional Review Board (no. 22781). All subjects were healthy
nonsmokers. A total of seven subjects were used in the gene
expression portion of this study (three males and four females),
with a mean age of 27.14 (62.9) y. Lung macrophages from an
additional four healthy subjects were used for the protein
validation portion of the study (three females and one male), with
a mean age 28.25 (63.4) y.
Bronchoalveolar lavage and macrophage isolation
Subjects underwent flexible bronchoscopy following local anes-
thesia with lidocaine to the posterior pharynx and distal trachea/
carina with or without i.v. sedation per patient preference. A
bronchoscopewas inserted trans-orally and advanced through the
vocal cords. Bronchoalveolar lavage fluid was obtained from
tertiary airways via rinses with 20 ml of sterile saline followed by
10 ml of air and repeated for a total of five times per airway. Lung
macrophages were isolated as previously described (31, 32).
EV generation and isolation
A clinically derived mucoid strain of P. aeruginosa (DH1137, gift
from Dr. D. Hogan, Geisel School of Medicine at Dartmouth) was
grown overnight (20 h) in Luria–Bertani media. Whole cells were
pelleted five times (3500 3 g 20 min) then filtered (0.22 mM),
leavingconditionedmediacontaining theEVs.Mediawasadjusted
to pH 4.0. Isolation of EVs was performed by mixing 600 ml of
Resin Slurry E (Norgen Biotek, Thorold, ON, Canada) with
conditioned media, multiple inversions with a 10-min equilibra-
tion. Resin was pelleted with centrifugation at 8003 g for 10 min
(Sorvall Legend31R Benchtop Centrifuge), media was discarded,
and the tube was inverted to drain. To recover EVs, 500 ml of 13
PBS (pH 6.0) was added to resin, tube was vortexed and allowed a
10 min equilibration, and subsequently centrifuged at 4003 g for
10 min to pellet the resin. PBS containing EVs was centrifuged
https://doi.org/10.4049/immunohorizons.2000026
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two additional times (400 3 g 10 min) to remove any residual
resin.EVs in13PBSwerealiquotedandstoredat280°Cuntil use.
EV characterization
Negative staining transmission electron microscopy (TEM) was
done as previously described (33). Briefly, a 10-ml aliquot of EVs in
13 PBS was placed on top of carbon-coated formvar support film
on 300 mesh Cu grids (Electron Microscopy Science) for 1 min,
with excess liquid removed by blotting with filter paper. Sample
was immediately stained with 1% uranyl acetate, blotted, and air-
dried in a humidity-controlled chamber. The samples were
examined using an FEI (Thermo Fisher Scientific) Tecnai 12,
transmission electron microscope with an accelerating voltage of
120KVand images recordedusingDigitalMicrographsoftwarevia
a Gatan, Rio9 digital camera system. Cryogenic (cryo)-EV samples
were prepared on freshly glow-discharged C-flat copper grids
(Electron Microscopy Sciences), plunged into liquid nitrogen
cooled, liquified ethane, and stored in liquid nitrogen using an FEI
(ThermoFisher Scientific)Vitrobot set to 2- and4-s blotting times.
Cryo-TEM was carried out on a Phillips CM120 Cryo-TEM at
120KVaccelerating voltage. Imageswere collectedunder low-dose
conditions using Digital Micrograph software and a Gatan, Orius
4K digital camera system.
Nanoparticle Tracking Analysis (NTA) with the NanoSight
NS300 instrument (Malvern, Worcestershire, U.K.) was used to
determinemean EV particle size and concentrations as previously
described (34). For NTA, EV samples were diluted in PBS and
introduced into the sample chamber via syringe pump. The
following script was used for EVmeasurements: PRIME, DELAY
120, CAPTURE 30, and REPEAT 3. Other acquisition settings
included the following: camera level of 14, camera shutter speed
13 ms, camera gain 360, and laser blue 488. NTA postacquisition
settings were optimized and kept constant between samples.
Software used was NTA version 3.2 Dev. Build 3.2.16.
Experimental design and gene expression
Right upper lobe lung macrophages were used in this study, as
several studies have shown that the right upper lobe is the
predominant lung lobe affected in CF patients (26, 35), and our
previous work has shown regional differences in the phenotype of
lung macrophages (36, 37). Cells were plated in six-well tissue
culturedishes seededat 13 106 cells perwell.Cellswereallowed to
adhere for 60 min, followed by incubation in the presence or
absence (negative control) of P. aeruginosa EVs at a ratio of 100:1
(EVs/cell), per Cecil et al. (38), for up to 48 h. We have used the
48-h timepoint to simulate chronic infection.Control experiments
were performed as above, in the presence or absence of
Pseudomonas-derived LPS only (1000 ng/ml). RNA was isolated
via RNeasyMini Kit (QIAGEN, Germantown, MD), as outlined in
the manufacturer’s instructions, and quantitated on a Qubit 3.0
Fluorometer (Life Technologies, Carlsbad, CA). The digital
multiplexed NanoString nCounter human v3 Cancer/Immune
RNA expression assay (NanoString Technologies, Seattle, WA)
was performed according to the manufacturer’s instructions with
total RNA. Briefly, 200 ng total RNA was assayed by overnight
hybridization (65°C) with nCounter gene-specific reporter and
capture probes. Following a 20-h hybridization, reporter and
capture probes are washed away using the automated nCounter
Sample Prep Station and probe/target complexes are aligned and
immobilized in thenCounterCartridge.Cartridgesare thenplaced
in the nCounter digital analyzer for data collection. nSolver
Analysis software (NanoString, V3.0) was used for data analysis
including background correction by subtracting the mean of
the six negative controls included on the NanoString platform
and normalization using the average geometric mean of the
30 housekeeping genes included in the assay.
Immunoblotting
Total protein was obtained by lysing cells in 200 ml/well 23
Laemmli buffer with 5% 2-ME with 1% protease inhibitors and
boiling 97°C, 5 min. Lysates were run on 7.5 and 10% gels and
transferred to polyvinylidene difluoride membranes. Membranes
werewashed in Tris-buffered salinewith 0.1%Tween 20, cut, and
incubated overnight at 4°C in 5% BSA containing 1:5000 primary
unless otherwise noted. Primary Abs were the following: mono-
clonal mouse anti–b-actin (catalog no. ab8226; Abcam), mono-
clonal rabbit anti-CD14 (catalog no. 56082S; Cell Signaling
Technology), 1:2000 monoclonal mouse anti-CD74 (catalog no.
sc-20062; Santa Cruz Biotechnology), monoclonal rabbit anti–
HLA-DRA (catalog no. 97971T; Cell Signaling Technology), and
monoclonal rabbit anti-CD9 (catalog no. 13174S; Cell Signaling
Technology).Membraneswere thenwashed four times in TBST
and incubated at room temperature for 1 h in BSA-TBST
containing 1:5000 secondary. Secondary Abswere the following:
mouse IgGk-binding protein (catalog no. sc-516102; Santa Cruz
Biotechnology) and polyclonal goat anti-rabbit IgG (catalog no.
ab7090; Abcam). Membranes were then washed, exposed to
Chemiluminescent Substrate (Thermo Fisher Scientific), and
imaged using x-ray film.
Mass spectrometry
Sample was lysed in 8 M urea and 50 mM Tris HCl (pH 8.0)
containing 13 Roche Complete Protease Inhibitor. Lysates were
quantified by Qubit fluorometry (Life Technologies). A 20-mg
aliquot of each samplewas digested in solutionusing the following
protocol: sample was diluted in 25 mM ammonium bicarbonate,
and proteins were reduced with 10mMDTT at 60°C, followed by
alkylation with 50 mM iodoacetamide at room temperature.
Proteinsweredigestedwith 1mg trypsin (Promega) at 37°C for 18h.
The digest was quenched with formic acid and peptides cleaned
using solid-phase extraction using theEmporeC18 plate (3M). A
2-mg aliquot was analyzed by nano liquid chromatography/mass
spectrometry (MS)/MSwith aWatersNanoAcquityHPLCsystem
interfaced to a Thermo Fisher Scientific Fusion Lumos mass
spectrometer. Peptides were loaded on a trapping column and
elutedover a75-mmanalytical columnat350nl/min;bothcolumns
were packed with Luna C18 resin (Phenomenex) with a 60-min
gradient. Themass spectrometer was operated in data-dependent
mode, with MS and MS/MS performed in the Orbitrap at 60,000
full width at half maximum resolution and 50,000 full width at
https://doi.org/10.4049/immunohorizons.2000026
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halfmaximumresolution,respectively.A3-scycletimewasemployed
for all steps. Datawere searched using a local copy ofMascotwith
the following parameters: enzyme, trypsin; database, Uniprot–P.
aeruginosa strain American Type Culture Collection 15692
(forward- and reverse-appendedwith common contaminants);
fixed modification, carbamidomethyl (C); and variable modifi-
cations, oxidation (M), acetyl (protein N-term), deamidation
(NQ), and pyro-Glu (N-term Q).
Mass values were the following: monoisotopic/peptide mass
tolerance, 10 ppm; fragment mass tolerance, 0.02 Da; and max
missed cleavages, 2. Mascot DAT files were parsed into the
Scaffold software for validation and filtering and to create a
nonredundant list per sample. Data were filtered 1% protein and
peptide level false discovery rate and requiring at least two unique
peptides per protein.
DNA methylation array
Epigenome-wide DNA methylation profiling was performed via
the InfiniumMethylation EPIC Bead Chips (Illumina, San Diego,
CA) for the determination of methylation levels of more than
850,000 CpG sites, as previously described (39). Briefly, DNAwas
extracted from bronchoalveolar lavage–derived cells via Qiagen
DNeasyBlood andTissueKit. DNAwas quantitated on aQubit 3.0
Fluorometer (LifeTechnologies). Bisulfite conversion ofDNAwas
carried out with the Zymo EZ DNA methylation kit (Zymo
Research, Irvine, CA), and EPIC array hybridization and scanning
were performed at the University of Southern California Mole-
cular Genomics Core.
DNA methylation array data processing
Raw intensity data files from the MethylationEPIC BeadChips
were processed by the minfi R/Bioconductor analysis pipeline
(version 1.30) (40) with annotation file version ilm10b4.hg19.
Probes known to cross-hybridize; probes associated with known
single-nucleotide polymorphisms, non-CpGs, and sex chromo-
somes; and probes failing to meet a detection p value of 0.05 in
$20%sampleswere excluded. Location ofCpGsweredetermined
by the method of Zhou et al. (41). Genomic contexts and CpG
relation to CpG islands were provided in the Illumina EPIC
annotation file. The promoter transcriptional context was defined
as either having a TSS200 or TSS1500 annotation, or both, in the
column UCSC_RefGene_Group (transcription start site). CpGs in
the promoter context were any with either Promoter_Associated
or Promoter_Associated_Cell_type_specific in the Regulatory_
Feautre_Groupannotation.Likewise, thegenebody transcriptional
context was defined as having a body in the UCSF RefGene Group
annotation. The enhancer context was defined as having a
FANTOM5 enhancer record. DNA methylation array data have
been deposited into Gene Expression Omnibus under https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142801. Please
FIGURE 1. Characterization of EVs from P. aeruginosa.
EVs from P. aeruginosawere isolated as described inMaterials and Methods. For visualization, EVs were negatively stained for TEM (A) or flash frozen
for cryo-electron microscopy (B). NTA via NanoSight NS300 was used for EV particle counting and sizing (C).
https://doi.org/10.4049/immunohorizons.2000026
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contact corresponding author D.A.A. (David.A.Armstrong@hitch-
cock.org) for a token to access these data.
Statistical analysis
All gene expression data were presented as means 6 SD.
GraphPad Prism (v7.0) analysis was used for paired sample t tests.
Differential gene expression analysis of NanoString data was
conductedusing edgeR (v3.26.8) and limma (v3.40.6) packages inR
(v3.6.1) (42,43).Thenormalizeddata fromNanoStringwere scaled
to counts per million. Five hundred and forty-one genes with.10
cpm in at least two samples were used for downstream analysis.
Likelihood ratio tests were conducted after fitting the gene
expression data to a negative binomial generalized linear model.
Three hundred and ten genes were determined as differentially
expressed based on its likelihood ratio test false discovery rate
value threshold of 0.05.
RESULTS
Characterization of EVs
Negative stain TEM was used to visualize isolated P. aeruginosa
EVs (Fig. 1A). EVs were heterogeneous in size with a range of
30–600 nm in diameter. EVs show characteristic concave appear-
ance common in negative staining. Additionally, cryo-electron
microscopy was used to further visually confirm EV size range
(Fig. 1B), and NTA was used for particle counting, sizing, and
visualization. Several batches of P. aeruginosa EVs were isolated and
usedover thecourseof the study.Arepresentativeparticle tracecurve
from one batch of P. aeruginosa EVs analyzed via the NanoSight
NS300 nanoparticle tracking instrument is shown in Fig. 1C. Mean
particle diameterwas 191.6 nM (694.4). Typical EV particle yield
from a starting volume of 35 ml of P. aeruginosa–conditioned
TABLE I. 26 Proteins identified by MS from P. aeruginosa EVs
Protein Accession Number Molecular Mass (kDa) Gene Protein Compartmental Location
Elastase P14756|ELAS_PSEAE 54 lasB Extracellular
B-type flagellin P72151|FLICB_PSEAE 49 fliC Extracellular
Chitin-binding protein Q9I589|CBPD_PSEAE 42 cbpD Extracellular
Outer membrane porin P13794|PORF_PSEAE 38 oprF Outer membrane vesicle
PhoP/Q outer membrane protein H1 G3XD11|G3XD11_PSEAE 22 oprH Outer membrane vesicle
Protease Las A P14789|LASA_PSEAE 46 lasA Extracellular
Elongation factor Tu P09591|EFTU_PSEAE 43 tufA Cytosol
FigM Q9HYP5|Q9HYP5_PSEAE 11 flgM
Lipid A deacylase Q9HVD1|PAGL_PSEAE 18 pagL Outer membrane vesicle
Thioredoxin Q9X2T1|THIO_PSEAE 12 trxA Cytosol
Osmotically inducible lipoprotein OsmE Q9HUT7|Q9HUT7_PSEAE 13 osmE Outer membrane
Uncharacterized protein Q9HWS1|Q9HWS1_PSEAE 16 PA4107
Uncharacterized protein Q9HZG8|Q9HZG8_PSEAE 12 PA3040
Chaperone protein DnaK Q9HV43|DNAK_PSEAE 68 dnaK Cytosol
Arginine/ornithine binding protein G3XD47|G3XD47_PSEAE 28 aotJ Extracellular
B-type flagellar hook-associated
protein
Q9K3C5|FLID2_PSEAE 49 fliD Extracellular
Probable peroxidase Q9HY81|Q9HY81_PSEAE 22 PA3529
DNA-binding protein HU P05384IDBHB_PSEAE 9 hupB Cytosol
Usp domain-containing protein Q9HYT5|Q9HYT5_PSEAE 16 PA3309 Outer membrane vesicle
OmpA-like domain-containing protein Q9I5A7|Q9I5A7_PSEAE 25 PA0833
Lysyl endopeptidase Q9HWK6|LYSC_PSEAE 48 prpL Extracellular
Uncharacterized protein Q9I4N7|Q9I4N7_PSEAE 13 PA1093
Uncharacterized protein Q9I384|Q9I384_PSEAE 10 PA1641
4-hydroxyphenylpyruvate dioxygenase Q9I576|HPPD_PSEAE 40 hpd
Alkyl hydroperoxide reductase C Q9I6Z3|Q9I6Z3_PSEAE 21 ahpC Cytosol
Probable cold-shock protein Q9I4H8|Q9I4H8_PSEAE 8 PA1159 Cytosol
TABLE II. Top 20 cytokines/chemokines altered in lung macrophages
with P. aeruginosa EV treatment
Normalized Read Counts (6SD)a
Gene Untreated EV Treated (48 h)
IL-1a 170 (80) 3,661 (960)
IL-1b 370 (248) 27,130 (11,310)
IL-6 3.3 (4.3) 1,810 (1,230)
IL-8 1,502 (1,793) 102,843 (43,186)
IL-10 1.6 (0.6) 69 (44)
IL-19 1.0 (0.1) 679 (386)
TGF-b1 338 (33) 388 (74)
TNF 37 (21) 357 (153)
CCL2 (MCP-1) 48 (29) 3,861 (1,882)
CCL3 (MIP-1a) 3,653 (452) 10,822 (6,354)
CCL4 (MIP-1b) 183 (246) 4,136 (2,493)
CCL7 (MCP-3) 4.6 (4.2) 226.5 (144.3)
CCL18 (MIP-4) 14,051.3 (10,181.1) 5,355.1 (4,644.1)
CCL20 (MIP-3a) 152.8 (221.1) 8,081.9 (4,137.4)
CCL23 (MIP-3) 270.6 (195.8) 71.5 (34.2)
CXCL1 (GROa) 83.6 (138.9) 31,247.4 (18,633.5)
CXCL2 (GROb) 146.0 (92.1) 5,344.8 (4,184.8)
CXCL3 (GROg) 290.9 (276.0) 16,089.7 (8,477.7)
CXCL5 (ENA-78) 1,765.1 (2,118.8) 40,783.8 (6,306.1)
CXCL16 (SRPSOX) 1,325.7 (1,792.7) 2,589.1 (541.1)
n = 7 subjects.
aNanoString PanCancer/Immunology gene expression assay.
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media was 4.253 109 total particles, corresponding to 1.23 108
particles/ml of media. A representative video of the P. aeruginosa
EV particles passing through the 488-nM laser light of the
NanoSight NS300 instrument is presented in the supplemental
files as Supplemental Video 1.
A proteomics analysis was used to further characterize the
P. aeruginosa EVs used in this study. MS was performed by MS
(Bio-Works, Ann Arbor, MI). A total of 26 proteins were
detected by MS, including numerous outer membrane proteins
such as elastase, LasA, OmpF, OmpH, OsmE, PagL, and PA3309,
as well as extracellular and cytosolic P. aeruginosa proteins. A
complete list of the proteins identified, their accession numbers,
associated genes, and compartmental locations are shown in
Table I.
Cytokine/chemokine and MHC gene expression
Gene expression of numerous cytokines and chemokines were
altered in lung macrophages following 48-h treatment with
P. aeruginosa EVs (Table II). A number of proinflammatory
molecules such as IL-1b, IL-8, and CXCL1 were notably higher,
whereas two anti-inflammatory genes IL-6 and IL-10 were also
higher. CCL18 andCCL23 andT andB cell chemoattractantswere
conspicuously lower.
Interestingly,P. aeruginosaEVshad a considerable suppressive
effect on major histocompatibility molecule gene expression.
MultipleMHC class II genes, in all subjects, were downregulated
after 48 h of P. aeruginosa EV treatment (Fig. 2), including HLA-
DRA, HLA-DPA1, HLA-DPB1 (p , 0.0001), HLA-DRB3, HLA-
DMB (p , 0.001), and HLA-DRB4 (p , 0.01). Additionally, gene
expression of MHC class II–related molecules CD74 (HLA-DR
Ag–associated invariant chain), cathepsin S (CTSS) (p , 0.0001)
and CD9 (tetraspanin-29) (p, 0.001) were suppressed following
48-h P. aeruginosa EV treatment. Furthermore, two MHC class I
molecules, HLA-A and HLA-B (p , 0.001), were suppressed as
well under our infection model experimental conditions
(Supplemental Fig. 1). A full list of the 310 differentially expressed
FIGURE 2. MHC class II– and class II–related gene expression is suppressed in lung macrophages following P. aeruginosa EV treatment.
HLA class II subunits -DRA and -DRB, along with paralogues -DP and enzyme -DM show decreased gene expression in all subjects (n = 7).
Additionally, gene expression is suppressed for class II–related molecules CD74, CD9, and cathepsin L, 48 h after EV treatment in lung macro-
phages. **p , 0.01, ***p , 0.001, ****p , 0.0001.
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genes following 48-h P. aeruginosa EV treatment is presented in
Supplemental Table I.
To examine the potential contribution of LPS alone, which is
contained on the surface of EVs, we conducted additional
experiments using Pseudomonas-derived LPS in vitro. Interest-
ingly, the effects of P. aeruginosa EVs on lung macrophages noted
above were very similar to those effects seen in in vitro
experiments with Pseudomonas-derived LPS alone shown in
Table III. Alterations of cytokine/chemokine gene expression as
well as decreases of MHC-related molecules occurred with 48-h
LPS treatment (1000 ng/ml), indicating that LPS contained either
on orwithin P. aeruginosaEVswas responsible formuch, if not all,
of these gene expression changes, therefore establishing the
relevance of testing an infection model with EVs as a diffusible
virulence agent.
MHC-related protein levels in lung macrophages
As an independent validation of the gene expression results, we
next measured protein levels in lung macrophages untreated or
exposed to P. aeruginosa EVs for 24 and 48 h. Lung macrophages
from an additional four subjects were used in this portion of the
studywith representative results presented in Fig. 3. Total cellular
protein of CD74 and CD9 were partially reduced at 24 h of EV
treatment and further reduced at the 48-h time point. The MHC
moleculeHLA-DRAwas increased at 24h butmodestly decreased
by 48 h. However, it is not particularly surprising to observe only
modest decreases in MHC-DRA and -DRB proteins at 48 h given
their half-lives of 20–50 h on human cells (44, 45) and that others
have noted cell surface stabilization of MHCmolecules with TLR
ligand engagement (46). As additional confirmation,we showboth
geneexpressionandprotein analysis forCD14, amolecule thatwas
significantly upregulated in our infection model (Supplemental
Fig. 2).
To explore the possible cellular mechanism of widespread
reduction of MHC-related molecules in our infection model, we
leveraged genome-wide DNAmethylation data from the Illumina
EPIC DNA methylation array and focused on regulatory regions
associated with MHC molecules. P. aeruginosa EVs result in
altered DNA methylation in lung macrophage MHC genes. We
observed significant hypomethylation associated with P. aerugi-
nosa EV treatment at three CpG sites in exon 8 of complement
factor B (CFB) gene, an MHC class III gene. CFB gene body
hypomethylation related with P. aeruginosa EV treatment ranged
from5.1 to 18.8% (Table IV). These differentiallymethylatedCpGs
in the gene body of CFB are situated between MHC class I and II
regions (Supplemental Fig. 3). We next tested the correlation
between theirmethylation levelandexpressionofMHCgenes.We
observed a strong correlation between DNA methylation of the
CFB gene body CpGs and gene expression of bothHLA-DRA (Fig.
4A–C) andHLA-DRB3 (Fig. 4D–F). A detailed correlation matrix
heatmap of allCFBCpGs on theEPIC array and allMHCgenes on
TABLE III. Gene expression changes in lung macrophages with
P. aeruginosa EV treatment versus LPS only
Normalized Read Countsa
P. aeruginosa EVs LPS Only
Gene Untreated EV Treated Untreated LPS Treated
CCL3 362 10,822 262 11,336
CCL3L1 436 13,778 238 15,346
CCL4 183 4,136 81 4,608
CCL18 14,051 5,355 6,762 3,409
CD14 788 7,891 720 6,187
CD44 2,426 5,581 3,444 5,774
CD74 8,574 1,947 6,127 1,240
CD81 6,882 3,512 6,359 3,368
CTSS 7,537 3,974 6,103 3,260
CXCL2 146 5,345 60 3,764
CXCL3 291 16,090 74 13,847
CXCL5 1,765 40,784 708 39,122
HLA-A 4,564 2,287 3,204 2,086
HLA-B 4,015 2,351 4,153 2,823
HLA-DRA 15,646 3,758 11,216 2,430
HLA-DRB3 5,002 1,413 3,820 925
IL-1b 370 27,129 176 22,714
IL-1RN 229 1,086 463 2,502
IL-8 1,502 102,843 766 67,858
LAMP1 2,631 1,727 3,707 2,095
LGALS3 5,035 1,840 4,480 1,890
MARCO 1,912 652 880 152
MRC1 1,046 1,652 669 2,276
S100A8 407 2,492 342 2,638
SH2D1B 765 18,478 347 17,515
n = 2.
aP. aeruginosa–derived LPS (1,000 ng/ml) 48 h.
FIGURE 3. Protein levels of MHC-related molecules decrease in lung
macrophages exposed to P. aeruginosa EVs for up to 48 h.
MHC class II–related proteins CD74 and CD9 decrease after 48 h but
show some variability at the 24 h time point. HLA-DR subunits were
modestly diminished at 48 h after P. aeruginosa EV treatment. TLR
engagement has been reported to partly stabilize HLA-DR surface
molecules, potentially leading to a modest depletion at the protein
level. A complement of four additional subjects were used for cellular
protein studies (see Materials and Methods). Responses were similar in
three of four subjects.
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the NanoString Cancer/Immune gene expression panel is shown
in Fig. 5, with the exon 8 containing CpGs highlighted.
DISCUSSION
The goal of this study was to determine if EVs, lipid bilayer
vesicles secreted from P. aeruginosa, could alter lung macrophage
gene expression, specifically at MHC genes associated with Ag
presentation and pathogen clearance. We have used human lung
macrophages and P. aeruginosa EVs as an in vitro model for lung
infection, simulatinghowmicrobialEVsmaydiffuse somedistance
from their cell of origin, potentially affecting innate immune cells
not in direct physical contact with individual microbes at sites of
bacterial colonization in the lung. Our results demonstrate that
when macrophages are exposed to P. aeruginosa EVs, MHC-
related genes and protein levels are suppressed. Additionally, we
observed hypomethylation of a DNA regulatory region situated
directly betweenMHC class I and class II genes within CFB gene
body. Hypomethylation of three closely situated CpGs within the
CFB gene showed strong correlation with decreased MHC gene
expression, hence the potential driving mechanism of MHC class
II mRNA suppression.
InCF, lungmacrophageshavebeen shown to exhibit decreased
phagocytosis and defective bacterial clearance (21, 22, 47). This
phenotype is likely influenced by both intrinsic (i.e., CFTR
expression) (48) and extrinsic factors (i.e., polymicrobial
environment) (49, 50). A number of recent studies have examined
howvirulence andotherpathogen-derived factors aswell aswhole
EVs can affect host cells in a pathogen–host interaction. Milillo
et al. (51) showed that RNA from Brucella abortus contributes to
inhibit MHC class II–restricted Ag presentation in macrophages.
Additionally, Bomberger et al. (10) showed that P. aeruginosa
virulence factor Cif inhibits TAP function and MHC class I Ag
presentation in epithelial cells. Also, Park et al. (52)were one of the
first studies to show that outer membrane vesicles or EVs from
P. aeruginosa could cause pulmonary inflammation in vivo in the
absence of whole bacteria. Finally, Cecil et al. (38) demonstrated
that EVs from oral pathogens P. gingivalis, Treponema denticola,
and Tannerella forsythia have significant immunomodulatory
effects on monocytes and macrophages.
In this report, we demonstrate for the first time, to our
knowledge, that EVs from a common CF pathogen, P. aeruginosa,
suppress expression of MHC-related molecules in human lung
macrophages. Nine different MHC class II–related genes/
molecules including HLA-DRA, -DRBs, -DMB, and -DPs (chro-
mosome 6); CD74 (chr5); CD9 (chr1); and CTSS (chr12) are
diminished with P. aeruginosa EV exposure. HLA-DRA and -DRB
are the heterodimeric subunits of the MHC II complex that bind
processed antigenic fragments within the phagolysosome (27).
HLA-DMB is the enzyme that removes CLIP from the HLA-DR
cleft so that the antigenic fragments can bind (27). HLA-DP are
class II b-chain paralogues. CD74, also called Ii, is the class
II invariant chain that initially blocks the MHC II cleft in the
FIGURE 4. CFB Exon 8 CpGs methylation shows strong correlation to HLA-DRA and HLA-DRB3 gene expression.
Correlation coefficients and linear regression p values were determined for CpGs in exon 8 (cg12124018, cg21606287, and cg01143314) associated
with gene expression of HLA-DRA (A–C) and HLA-DRB3 (D–F). Correlations were calculated using the Spearman rank correlation method. Linear
regression lines and its 95% confidence intervals is indicated by the blue lines and gray bands, respectively.
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FIGURE 5. Correlation plot of CFB-associated CpG methylation and MHC-related gene expression.
Strong correlation (R . 0.55, Spearman rank correlation method) exists between methylation of CFB CpGs (cg21606287, cg01143314, and
cg12124018) and gene expression of multiple MHC-related genes. Hypomethylated CFB CpGs in exon 8 are highlighted in black rectangles. Size of
the circles indicates the absolute value of corresponding correlation coefficients. Color indicates the direction of correlation from strong negative
correlation (dark red, correlation coefficient = 21) to strong positive correlation (dark blue, correlation coefficient = 1).
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Ag-processing compartment or phagolysosome (27). CD9 regu-
latesMHCII traffickingwithin the cell (53). CTSS is cathepsin S, a
lysosomal cysteine protease that degrades CD74 and pathogen
peptideswithin the phagolysosome (27). All of thesemolecules are
intimately involved in MHC class II Ag processing and pre-
sentation to CD4+ T cells as a bridge between innate and adaptive
immunity during a pathogen infection.
Additionally, we asked if the MHC-related effects seen may
be attributed to LPS alone or some other yet-to-be-identified
virulence factor within EVs. Interestingly, experiments with LPS
alone demonstrated that LPS itself was responsible for much, if
not all, of these gene expression changes in lung macrophages in
our infection model.
The response we are observing has some of the hallmarks of
endotoxin tolerance, however, other aspects, specifically IL-1b and
MHCmolecules, are not consistent with tolerance. Studies on the
mechanismof endotoxin tolerancehave longhistory but are still in
constant progress. However, the exact mechanism of endotoxin
tolerance is still elusive, and many questions remain to be
answered (54). In our infection model, it may be that human lung
macrophages contain cell-specific subsets of tolerizeable genes
andnontolerizeablegeneswithdifferentbehaviorsafter endotoxin
stimulation. What we are observing may be a combination of an
active host response (i.e., endotoxin tolerance) and an active
pathogen-derived process to circumvent the host’s immune
response. Future studies should be directed toward answering
this question.
Furthermore, we have identified, via genome-wide DNA
methylation analysis, three specific CpGs on chromosome 6
within the CFB gene situated directly between MHC class I and
MHC class II regions that may serve as a DNA regulatory region
forMHCmolecule gene expression. The CpGs of CFB are located
;500 kb from the class II HLA-DRA gene and 700 kb from the
class I HLA-B gene. Hypomethylation (range 5.1–18.8%) of these
CpG sites is strongly correlated with gene expression of multiple
MHC genes.
Over 200 MHC molecules are clustered in a 3-MB region of
chromosome 6 in humans. Multiple DNA regulatory regions
(i.e., enhancers, silencers, and DHS regions) may be involved in
MHCmolecule coregulation (55). One type of regulatory element,
enhancers, do not always act upon the closest gene promoter but
can bypass neighboring genes to regulate genes located more
distantly along a chromosome (56). And in some cases, individual
enhancers have been found to regulate multiple genes (57). One of
the most extreme examples is the location of a DNA regulatory
element, in this case an enhancer, is located 1 Mb upstream from
the SonicHedgehog (SHH) gene,within an intron of the unrelated
LMBR1 gene (58, 59). We believe CFB gene methylation could be
another example of a distal DNA regulatory element located in a
neighboring gene (gene A; i.e.,CFB), in which hypomethylation in
the gene CFB results in transcriptional repression of gene B
(i.e., MHC genes).
In addition to theMHC genes on chromosome 6, otherMHC-
related genes, such as CTSS and CD74, are located on alternate
chromosomes (chromosomes 1 and5, respectively).This suggests
that P. aeruginosa EVs possess some factor(s) that specifically
target MHC molecule suppression regardless of their chromo-
somal location as an immune evasion strategy. The exact mech-
anism of gene regulation across multiple differing chromosomes
remains to be determined and should be the focus of future
investigations.
This study has a number of strengths; however, this work also
has a number of limitations. We cannot rule out that virulence
factors or other yet-unidentified molecules within P. aeruginosa
EVsbeyondLPSmaybecontributing to theeffectsweare seeing in
our infection model. Additionally, it is not currently known if the
response seen is an active host response (i.e., tolerance), an
operative pathogen process to circumvent host defenses or some
combination of both.
In conclusion, in our infection model, we have demonstrated
the immunosuppressive potential of P. aeruginosa EVs on lung
macrophages.Theseeffects appear tobe largelyattributable toLPS
contained on or within EVs and may be contingent upon the
diffusible nature of EVs. In the polymicrobial community of a CF
lung infection, the local milieu is significantly more complicated
than presented in our model, but based on the observations
demonstrated in this study, we suggest that the downregulation of
MHC molecules by P. aeruginosa EVs may be contributing, along
with other extrinsic factors from P. aeruginosa and additional
pathogens, to decreased Ag presentation and pathogen clearance
in lung infection.
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TABLE IV. Chromosomal location of HLA genes and CFB hypomethylated CpGs
Gene Name/EPIC cg ID Class Gene/CpG Location Hypomethylation Change (%)
HLA-A I chr6: 29,881,755–30,002,076
HLA-B I chr6: 31,259,328–31,347,305
CFB III chr6: 31,945,650–31,952,084
CFB (cg12124018) III chr6: 31,948,906 215.8
CFB (cg21606287) III chr6: 31,948,928 218.8
CFB (cg01143314) III chr6: 31,948,934 25.1
HLA-DRA II chr6: 32,414,554–32,419,764
HLA-DRB3 II chr6: 32,449,765–32,462,852
HLA-DMB II chr6: 33,025,327–33,043,825
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Supplemental Figure 1
Supplemental Fig 1. MHC Class I gene expression is suppressed in lung macrophages with 48 hour P.a. EV treatment.
NanoString nCounter gene expression assay utilizing the cancer/immune panel of 770 genes was used to measure 
MHC Class I gene expression. HLA-A and HLA-B mRNA was diminished post EV-treatment. *** P < 0.001.
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Supplemental Figure 2. Gene expression and protein expression on CD14 in lung macrophages increases 
with P. aeruginosa EV treatment.
CD14 gene expression in lung macrophages from all subjects (n=7) increases with P.a. EV-treatment (A). Protein 
expression increase at 48 hours confirms and validates mRNA measurement (B).***P < 0.001.
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Supplemental Figure 3. Schematic representation of MHC gene clustering on chromosome 6.  MHC 
class I genes, in general are situated more toward 5’ end of chromosome 6 segment and class II genes situated 
more 3’ on chromosome 6. Complement factor B (CFB), one of approximately 60 MHC class III genes is 
situated directly in between class I & II. Schematic shows examples of genes contained in this MHC class III 
region of chromosome 6 (not all inclusive or to exact scale). CFB contains 18 exons. The three CpGs identified 
as significantly hypomethylated are located in exon 8 of the CFB gene.
Supplemental Video 1 
Nanoparticle tracking analysis (NTA) of P. aeruginosa extracellular vesicles (EVs).  
P. aeruginosa extracellular vesicles were measured by NTA. EVs were isolated via 
affinity resin, diluted in phosphate-buffered saline, and introduced into the NanoSight 
NS300 sample chamber via syringe pump. The following script was used for EV 
measurements: PRIME, DELAY 120, CAPTURE 30, REPEAT 3. Other acquisition 
settings included the following: camera level, 14; camera shutter speed, 13 
milliseconds; camera gain, 360; and laser, blue 488. NTA post-acquisition settings were 
optimized and kept constant among samples. Software used was NTA version 3.2 Dev. 
Build 3.2.16. 
 
